Larimar Therapeutics Inc (LRMR) with a beta value of 0.83 appears to be a promising investment opportunity.

On Monday, Larimar Therapeutics Inc (NASDAQ: LRMR) opened lower -21.72% from the last session, before settling in for the closing price of $6.17. Price fluctuations for LRMR have ranged from $3.80 to $13.68 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Company’s average yearly earnings per share was noted -44.77% at the time writing. With a float of $37.01 million, this company’s outstanding shares have now reached $63.81 million.

Let’s determine the extent of company efficiency that accounts for 42 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Larimar Therapeutics Inc (LRMR) Breakdown of a Key Holders of the stock

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Larimar Therapeutics Inc is 42.00%, while institutional ownership is 60.93%. The most recent insider transaction that took place on Feb 16 ’24, was worth 499,998. In this transaction Director of this company bought 57,208 shares at a rate of $8.74, taking the stock ownership to the 564,798 shares. Before that another transaction happened on Feb 16 ’24, when Company’s Director bought 4,290,617 for $8.74, making the entire transaction worth $37,499,993. This insider now owns 6,151,406 shares in total.

Larimar Therapeutics Inc (LRMR) Recent Fiscal highlights

According to the Wall Street analysts, stocks earnings will be around -44.77% per share during the next fiscal year.

Larimar Therapeutics Inc (NASDAQ: LRMR) Trading Performance Indicators

Check out the current performance indicators for Larimar Therapeutics Inc (LRMR). In the past quarter, the stock posted a quick ratio of 13.10.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.15, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.65 in one year’s time.

Technical Analysis of Larimar Therapeutics Inc (LRMR)

Looking closely at Larimar Therapeutics Inc (NASDAQ: LRMR), its last 5-days average volume was 1.8 million, which is a jump from its year-to-date volume of 0.61 million. As of the previous 9 days, the stock’s Stochastic %D was 35.56%. Additionally, its Average True Range was 0.70.

During the past 100 days, Larimar Therapeutics Inc’s (LRMR) raw stochastic average was set at 26.49%, which indicates a significant decrease from 46.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 116.02% in the past 14 days, which was higher than the 87.73% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $7.14, while its 200-day Moving Average is $7.75. However, in the short run, Larimar Therapeutics Inc’s stock first resistance to watch stands at $5.66. Second resistance stands at $6.50. The third major resistance level sits at $7.82. If the price goes on to break the first support level at $3.50, it is likely to go to the next support level at $2.18. Now, if the price goes above the second support level, the third support stands at $1.34.

Larimar Therapeutics Inc (NASDAQ: LRMR) Key Stats

There are currently 63,807K shares outstanding in the company with a market cap of 311.21 million. Presently, the company’s annual sales total 0 K according to its annual income of -36,950 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -15,500 K.